AD-RIDDLE: Real-World Implementation, Deployment And Validation Of Early Detection Tools And Lifestyle Enhancement

AD-RIDDLE：早期检测工具和生活方式增强的实际实施、部署和验证

• 批准号: 10083470
• 金额: $ 49.75万
• 依托单位: NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10083470
• 关键词: AD; RIDDLE; Real; World; Implementation

Alzheimer's disease (AD), the main cause of dementia, is one of the major global health challenges of our time. This disabling disorder affects 55 million people worldwide, with costs above $1.3 trillion. With 67 million people at risk for AD dementia (prodromal and preclinical AD) in Europe alone, it is a major unmet public health need, with increasing burden for European economies, healthcare and social care systems and a concern for the future. Yet, prevention and early detection strategies have been lacking. Recent advances in disease-modifying therapies and the huge potential benefits of preventive multidomain interventions based on modifiable lifestyle and vascular factors (prevention potential ~ 40%) provide new opportunities. New developments in blood-based biomarkers (BBMs) and digital cognitive tests enable broader, cost-effective testing. The AD-RIDDLE platform is envisioned to revolutionize how AD is detected and diagnosed, prevented and treated across healthcare settings (HCS). AD-RIDDLE centres around a toolbox platform concept, providing a series of validated tools at each key step to enable HCS and practitioners to deploy enhanced AD management across diverse patient populations. The AD-RIDDLE toolbox platform will include a) community outreach tools to increase awareness/activation on AD prevention; b) combination of easily available, clinically validated biomarkers: digital cognitive tools and BBMs, for early detection of AD dementia risk; c) validated algorithms supporting clinical decisions, to identify people who can benefit from specific preventive therapies (pharma and/or non-pharma) using precision prevention approach. The toolbox usability and efficacy with be tested in realworld settings. We expect that the AD-RIDDLE modular and flexible design can facilitate broad uptake from different healthcare systems, and its tools can advance research to develop cost-effective preventive therapies for AD, with scalability for other dementias

阿尔茨海默氏病（AD）是痴呆症的主要原因，是我们这个时代的主要全球健康挑战之一。这种残疾疾病影响了全球5500万人，成本超过1.3万亿美元。仅欧洲就有6700万人有痴呆症的风险（前奏和临床前广告），这是一个主要的未满足的公共卫生需求，对欧洲经济体，医疗保健和社会护理系统的负担增加，并且对未来的关注。然而，缺乏预防和早期检测策略。基于可修改的生活方式和血管因素（预防潜力〜40％）的预防多域干预措施的疾病改良疗法的最新进展以及预防性多域干预的巨大好处提供了新的机会。基于血液的生物标志物（BBM）和数字认知测试的新事态发展可以更广泛，具有成本效益的测试。设想的AD-Riddle平台将在整个医疗机构（HCS）（HCS）中彻底改变了AD的检测和诊断，预防和治疗。 Ad-Riddle围绕工具箱平台概念，在每个关键步骤中提供一系列经过验证的工具，以使HCS和从业人员能够在不同的患者人群中部署增强的广告管理。 Ad-Riddle工具箱平台将包括a）社区外展工具，以提高对AD预防的认识/激活； b）易于使用的临床验证的生物标志物的组合：数字认知工具和BBM，以早日检测痴呆症风险； c）通过精确预防方法，验证了支持临床决策的算法，以确定可以从特定的预防疗法（制药和/或非药物）中受益的人。在Realworld设置中测试工具箱的可用性和功效。我们预计Ad-Riddle模块化和灵活的设计可以促进不同的医疗保健系统的广泛吸收，其工具可以提高研究以开发成具有成本效益的预防疗法，并具有针对其他痴呆症的可扩展性